Johnson & Johnson (JNJ) is Skandinaviska Enskilda Banken AB publ’s 3rd Largest Position
Skandinaviska Enskilda Banken AB publ reduced its stake in Johnson & Johnson (NYSE:JNJ) by 33.3% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 2,084,000 shares of the company’s stock after selling 1,039,808 shares during the period. Johnson & Johnson makes up about 2.6% of Skandinaviska Enskilda Banken AB publ’s portfolio, making the stock its 3rd largest position. Skandinaviska Enskilda Banken AB publ owned 0.08% of Johnson & Johnson worth $259,563,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Cheviot Value Management LLC boosted its position in Johnson & Johnson by 3.1% in the fourth quarter. Cheviot Value Management LLC now owns 107,813 shares of the company’s stock valued at $12,421,000 after buying an additional 3,245 shares during the last quarter. Janus Capital Management LLC boosted its position in Johnson & Johnson by 11.2% in the fourth quarter. Janus Capital Management LLC now owns 2,722,996 shares of the company’s stock valued at $313,717,000 after buying an additional 273,944 shares during the last quarter. SRS Capital Advisors Inc. purchased a new position in Johnson & Johnson during the fourth quarter valued at $752,000. Wallace Capital Management Inc. boosted its position in Johnson & Johnson by 3.7% in the fourth quarter. Wallace Capital Management Inc. now owns 105,608 shares of the company’s stock valued at $12,168,000 after buying an additional 3,723 shares during the last quarter. Finally, City Financial Investment Co Ltd purchased a new position in Johnson & Johnson during the fourth quarter valued at $2,592,000. 66.10% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE JNJ) traded down 0.31% during mid-day trading on Friday, reaching $132.63. 4,792,761 shares of the company’s stock traded hands. Johnson & Johnson has a one year low of $109.32 and a one year high of $137.08. The firm has a market cap of $355.98 billion, a price-to-earnings ratio of 22.44 and a beta of 0.78. The firm’s 50-day moving average price is $132.88 and its 200 day moving average price is $127.04.
Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, topping analysts’ consensus estimates of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm had revenue of $18.84 billion for the quarter, compared to the consensus estimate of $18.94 billion. During the same period in the previous year, the firm posted $1.74 EPS. The business’s quarterly revenue was up 1.9% on a year-over-year basis. On average, equities analysts forecast that Johnson & Johnson will post $7.18 EPS for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 12th. Stockholders of record on Tuesday, August 29th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.53%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.
WARNING: “Johnson & Johnson (JNJ) is Skandinaviska Enskilda Banken AB publ’s 3rd Largest Position” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/20/johnson-johnson-jnj-is-skandinaviska-enskilda-banken-ab-publs-3rd-largest-position.html.
JNJ has been the topic of several research analyst reports. Vetr raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $128.54 price target on the stock in a report on Monday, April 24th. Jefferies Group LLC reaffirmed a “hold” rating and issued a $135.00 price target (down previously from $140.00) on shares of Johnson & Johnson in a report on Sunday, May 14th. J P Morgan Chase & Co raised shares of Johnson & Johnson from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $123.64 to $140.00 in a report on Monday, May 15th. UBS AG reaffirmed a “buy” rating and issued a $136.00 price target on shares of Johnson & Johnson in a report on Monday, May 15th. Finally, Stifel Nicolaus reaffirmed a “hold” rating and issued a $128.00 price target (up previously from $124.00) on shares of Johnson & Johnson in a report on Thursday, May 18th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $133.70.
In other news, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction dated Thursday, July 20th. The shares were sold at an average price of $136.72, for a total value of $11,291,841.52. Following the sale, the vice president now directly owns 226,693 shares in the company, valued at approximately $30,993,466.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now owns 230,342 shares in the company, valued at $30,667,733.88. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.